18F-FMT Uptake Seen Within Primary Cancer on PET Helps Predict Outcome of Non–Small Cell Lung Cancer
Open Access
- 16 October 2009
- journal article
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 50 (11), 1770-1776
- https://doi.org/10.2967/jnumed.109.066837
Abstract
L-[3-18F]-α-methyl tyrosine (18F-FMT) is an amino-acid tracer for PET imaging. We evaluated the prognostic significance of 18F-FMT PET in patients with non–small cell lung cancer. Methods: Ninety-eight patients (80 men and 18 women; age range, 42–82 y; median age, 69 y) with stage I–IV non–small cell lung cancer were enrolled in this study. They included 57 with adenocarcinoma, 31 with squamous cell carcinoma, 5 with large cell carcinoma, and 5 with other conditions. The median follow-up duration was 17.0 mo. A pair of PET studies with 18F-FMT and 18F-FDG was performed, and tracer uptake by the primary tumor was evaluated using the maximal standardized uptake value (SUVmax). Overall survival and disease-free survival were calculated by the Kaplan–Meier method. The prognostic significance was assessed by univariate and multivariate analyses. Results: The best discriminative SUVmax cutoffs for 18F-FMT and 18F-FDG in the primary tumors were 1.6 and 11, respectively. In the univariate analysis, a high SUVmax was significant in predicting poor overall survival for 18F-FMT (P = 0.0129) and 18F-FDG PET (P = 0.0481). According to histologic types, 18F-FMT and 18F-FDG uptake were a stronger prognostic predictor in adenocarcinoma than in nonadenocarcinomatous disease. Patients with a high SUVmax for 18F-FMT showed significantly worse disease-free survival rates than those with a low SUVmax, and multivariate analysis confirmed that a high SUVmax for 18F-FMT was an independent and significant factor in predicting a poor prognosis in patients with adenocarcinoma (P = 0.0191). Conclusion: Uptake of 18F-FMT in primary tumors was an independent prognostic factor in patients with pulmonary adenocarcinoma.Keywords
This publication has 26 references indexed in Scilit:
- Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinomaLung Cancer, 2009
- Prognostic Value of Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography Imaging in Patients With Advanced-Stage Non–Small-Cell Lung CarcinomaJournal of Clinical Oncology, 2008
- Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancerBritish Journal of Cancer, 2008
- Fluorine-18-α-Methyltyrosine Positron Emission Tomography for Diagnosis and Staging of Lung Cancer: A Clinicopathologic StudyClinical Cancer Research, 2007
- Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic RoleClinical Cancer Research, 2007
- Present role and future prospects of positron emission tomography in clinical oncologyCancer Science, 2006
- L‐type amino acid transporter 1 as a potential molecular target in human astrocytic tumorsInternational Journal of Cancer, 2006
- [18F]Fluorodeoxyglucose Uptake by Positron Emission Tomography Predicts Outcome of Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2005
- Evaluation of F-18 fluorodeoxyglucose (FDG) PET scanning for pulmonary nodules less than 3 cm in diameter, with special reference to the CT imagesLung Cancer, 2004
- Synthesis of isomers of 18F-labelled amino acid radiopharmaceuticalNuclear Medicine Communications, 1997